The present invention relates to an expanded population of human Breg cells having the phenotype CD19+CD73−;CD71+CD25+TIM-1+ and methods for producing the cell population of the invention. The invention also relates to pharmaceutical compositions comprising the cell populations of the invention and their use in the treatment of immune-mediated disorders.